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Rome, Forlì, Ferrara, Milan, and Pisa, ItalyObjectives This study sought to assess whether intracoronary adenosine or nitroprusside following
thrombus aspiration (TA) is superior to TA alone for the prevention of microvascular obstruction (MVO)
in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary
intervention (PCI).
Background MVO, due to its multifactorial pathogenesis, still occurs after TA in a sizeable portion of
patients.
Methods We performed a placebo-controlled, randomized, open-label, blind-examination, multicenter
trial. A total of 240 STEMI patients with Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade 0/1 were
randomly allocated 1:1:1 to receive adenosine (n ¼ 80), nitroprusside (n ¼ 80), or saline (n ¼ 80) given
distal to the occluded site after TA. The primary endpoint was the incidence of ST-segment resolution
(STR) >70% on surface electrocardiogram at 90 min after PCI. Secondary endpoints were angiographic
MVO incidence (TIMI ﬂow grade 2 or 3 with a myocardial blush grade <2) and major adverse cardiac
event (MACE) rate at 30 days as a composite of cardiac death, myocardial infarction, target lesion
revascularization, and heart failure requiring hospitalization.
Results STR >70% occurred in in 71% of adenosine-treated patients, in 54% of nitroprusside-treated
patients, and in 51% of saline-treated patients (p ¼ 0.009 and p ¼ 0.75, respectively, vs. saline).
Angiographic MVO occurred in 18% of adenosine-treated patients, in 24% of nitroprusside-treated
patients, and in 30% of saline-treated patients (p ¼ 0.06 and p ¼ 0.37, respectively, vs. saline). MACE
occurred in 10%, 14%, and 20% of patients, respectively (p ¼ 0.08 and p ¼ 0.29 vs. saline).
Conclusions In STEMI patients treated by PCI and TA, the additional intracoronary administration of
adenosine, but not that of nitroprusside, results in a signiﬁcant improvement ofMVO, as assessed by STR.
(J Am Coll Cardiol Intv 2013;6:580–9)ª 2013 by the American College of Cardiology Foundation
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and Acronyms
AV = atrioventricular
CI = conﬁdence interval
CK = creatine kinase
ECG = electrocardiogram
IRA = infarct-related artery
IV = intravenous
MACE = major adverse
cardiac event(s)
MVO = microvascular
obstruction
PCI = percutaneous coronary
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PPCI = primary percutaneous
coronary intervention
STEMI = ST-segment
elevation myocardial
infarction
STR = ST-segment resolution
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TIMI = Thrombolysis In
Myocardial Infarction
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581The prompt reopening of the infarct-related artery (IRA) by
primary percutaneous coronary intervention (PPCI) is the
main therapeutic goal in patients with ST-segment elevation
myocardial infarction (STEMI) (1). Yet, in about 30% to 50%
of patients, microvascular obstruction (MVO) reduces the
beneﬁcial effects of a successful recanalization of the IRA (2).
The prevention of MVO has been an intense ﬁeld of clinical
research in the past (3,4), with a renewed interest in the last few
years (5,6). Interestingly, in the TAPAS (Thrombus Aspira-
tion during Percutaneous coronary intervention in Acute
myocardial infarction Study) trial, thrombus aspiration (TA)
before stent implantation, as compared with standard PPCI,
improved the rate of complete resolution of ST-segment
elevation, a validated index of reperfusion (6). Of note, 90%
of patients were treated by intravenous (IV) abciximab, which
has been previously shown to lower the incidence ofMVO (7).
However, in this study, complete resolution of ST-segment
elevation was not obtained in 44% of patients despite TA,
and it did not translate into a reduction of infarct size (6). This
is not surprising because the pathogenesis of MVO after
PPCI is multifactorial, and ischemia–reperfusion injury plays
a key role (8).
Drugs able to dilate the microcirculation, such as adenosine
(9,10) or nitroprusside (11), might limit reperfusion injury.
Both drugs have been investigated in previous studies (12–21),
but study results are conﬂicting because of small sample size,
inadequate drug dosage, or lack of glycoprotein IIb/IIIa
administration orTA.Thus, wehave carried out a trial aimed at
establishing whether high doses of intracoronary adenosine or
nitroprusside improve myocardial perfusion in patients
undergoing primary or rescue PCI for STEMI and treated by
glycoprotein IIb/IIIa antagonists and TA (1).
Methods
Study design and population. The REOPEN-AMI
(Intracoronary Nitroprusside Versus Adenosine in Acute
Myocardial Infarction) trial is a placebo-controlled, random-
ized, open-label, blind-examination (PROBE), multicenter
trial of the effects of intracoronary adenosine or nitroprusside
on MVO in patients undergoing primary or rescue PCI and
TA and glycoprotein IIb/IIIa antagonist administration (22).
Six hospitals in Italy enrolled patients from September 2008 to
September 2011, with enrollment starting after local ethics
committee approval. Informed consent was obtained on
admission for each patient enrolled in the study. Inclusion
criteria were symptom onset <12 h before enrollment,From the *Institute of Cardiology, Catholic University of the Sacred Heart, Rome,
Italy; yU.O. Dipartimentale di Emodinamica e Cardiologia Interventistica, S. Pertini
Hospital, Rome, Italy; zU.O. Cardiologia, G. B. Morgagni–L. Pierantoni Hospital,
Forlì, Italy; xChair of Cardiology, Arcispedale S. Anna, Ferrara, Italy; kDepartment of
Cardiovascular Sciences, European Hospital, Rome, Italy; {U.O. Cardiologia Inter-
ventistica, Cardiologic Center Monzino, Milan, Italy; #Policlinico Casilino, Rome,ST-segment elevation of at least 2mm in 2 ormore contiguous
leads, and Thrombolysis In Myocardial Infarction (TIMI)
ﬂow grade 0/1 at baseline angiography. Exclusion criteria were
age <18 years, previous STEMI in the same territory of
current admission, cardiogenic shock, pregnancy, history of
renal failure (serum creatinine>3mg/dl), contraindications to
contrast agents or other study medications, paced rhythm,
frequent ventricular ectopy, left bundle branch block, pre-
excitation or other conditions or artifacts interfering with
interpretation of the ST segment, culprit lesion located in
a bypass graft, stent thrombosis, unidentiﬁed culprit lesion,
and left main disease.
Randomization and treatment. All PPCI patients received
aspirin (250 mg IV), clopidogrel (600 mg orally) in the
emergency department, whereas
IV bolus administration of abcix-
imab (0.25 mg/kg) and heparin
(5,000 IU) was performed before
PCI. A 12-h infusion of abcix-
imab followed the bolus.
In rescue PCI patients,
a weight-adjusted single IV dose
of tenecteplase was given, ranging
from 30 mg in patients<60 kg to
50 mg in those weighing90 kg.
Simultaneously, a 60 U/kg bolus
of unfractionated heparin was
administered up to a maximum
of 4,000 U followed by a 24-h
infusion of 12 U/kg/h (up to
amaximumof1,000U/h),with an
initial adjustment to maintain an
activated partial thromboplastin
time 1.5 to 2 times the upper
normal limit. All patients received
300 mg of clopidogrel, whereas
IV bolus administration of abcix-
imab (0.25mg/kg) was performed
before PCI, whereas a 12-h infu-
sion of abciximab followed the bolus. Thus, all patients,
underwent abciximab administration.
If eligible at the completion of diagnostic angiography, the
patient was randomized either to intracoronary adenosine
(120 mg as fast bolus followed by 2 mg given in 33 ml of saline
over 2 min as slow bolus), nitroprusside (60 mg as fast bolus
followed by 100 mg given in 33 ml of 5% glucose over 2 min as
slow bolus), or placebo (2 ml of heparinized saline as fastItaly; **Istituto Scienze della Vita, Scuola Superiore Sant’Anna, Pisa, Italy; and the
yyDepartment of Public Health and Infectious Diseases, Sapienza University of Rome,
Rome, Italy. The authors have reported that they have no relationships relevant to the
contents of this paper to disclose.
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582bolus followed by 33 ml of heparinized saline given over
2 min as slow bolus). Randomization took place through an
envelope opened by a trainee, so that a 1:1:1 ratio was ach-
ieved. Envelopes were arranged in a sequence for treatment
assignment, and the number of patients to be enrolled by each
center was decided at the start of the study (see the Online
Appendix for the number of patients enrolled by each center).
The nursing personnel were then asked to prepare the study
drugs. Both opening of the envelope and drug preparation
were performed after diagnostic angiography to establish
eligibility. TA was performed after wire crossing. The device
used for manual TA was left to the policy of each catheteri-
zation laboratory (all manual TA devices were 6-F compat-
ible). After TA, the device was removed, ﬂushed with saline,
reintroduced into the culprit vessel, advancing the tip beyond
the occlusion site, and then used for selective administration
of study drugs. Drugs were infused into the IRA only if distal
vessels were visualized after aspiration. Otherwise, balloon
pre-dilation was allowed before drug administration. If, for
mechanical reasons, the TA device could not be advanced
into the culprit vessel, drug administration was performed
through the guiding catheter after balloon pre-dilation. Acute
side effects were recorded by the interventional cardiologist
during and after the infusion into the IRA. In case of tran-
sient atrioventricular (AV) block, the operator was allowed to
restart the infusion after a few seconds in order to provide the
full dose of the drugs. In case of persistent AV block, the
operator was allowed to insert a temporary pacing catheter in
order to complete drug administration.
Study endpoints, assessment of outcomes, and deﬁ-
nitions. The primary endpoint was the rate, evaluated by
visual assessment, of ST-segment resolution (STR)>70% on
surface electrocardiogram (ECG) at 90 min after PCI.
Secondary endpoints were the rate of angiographic MVO
(TIMI ﬂow grade2 or 3 with a myocardial blush grade<2)
and of major adverse cardiac events (MACE) at 30 days as
a composite of cardiac death, myocardial infarction, target
lesion revascularization, and heart failure requiring hospitali-
zation. Furthermore, the rate of combined MVO (concor-
dance of lack of STR and angiographic MVO) was compared
between treatment groups and placebo (23). Enzymatic infarct
size deﬁned as the peak of creatine kinase (CK), CK-MB, and
troponin T (TnT) was also assessed. Details about the study
endpoint assessment are reported in the Online Appendix.
Statistical analysis. The following parameters were used for
the sample size calculation, using Statcalc (EpiInfo 3.5.1,
Centers for Disease Control and Prevention, Atlanta,
Georgia): power of 0.8, signiﬁcance level of 0.025, allocation
ratio of 1:1 with a common control, but 2 treatments, and an
effect size to be detected of 0.25, improvement of the primary
endpoint by 25%, which was obtained considering a STR of
45% in the placebo group (24), and an STR of 70% in the
treatment groups. Because theminimum sample size requested
was 237 patients, we decided to enroll up to 240 patients.Data distribution was assessed by the Kolmogorov-
Smirnov test. Variables that did not follow a normal distri-
bution were expressed as medians and interquartile ranges,
whereas other continuous variables were expressed as
mean  SD; categorical variables were expressed as pro-
portions. Comparison between categorical variables was done
using the chi-square test or Fischer exact test, as appropriate.
The Student t test or Mann-Whitney U test were used for
the comparison of continuous variables, as appropriate. A
per-protocol analysis regarding the primary endpoint was
performed after excluding patients with TA failure. Subgroup
analysis according to main clinical and angiographic data was
also performed by means of logistic regression analysis with
formal test for interaction. Data have been analyzed according
to the intention-to-treat principle.
Two-sided tests were used, and a p value <0.025 (using
the Bonferroni adjustment, alpha level/number of compar-
ison: 0.05/2) was the statistical signiﬁcance level. The soft-
ware SPSS 17.0 (SPSS Italia, Florence, Italy) was used for
all statistical analyses with the exception of subgroup analysis
performed with STATA 10.1 (StataCorp LP, College
Station, Texas).
Results
Study population. During the study period, 471 patients
were considered for inclusion and 240 patients were enrolled
according to eligibility criteria (Fig. 1). Patients enrolled
were randomized to adenosine (80 patients), nitroprusside
(80 patients), or saline (80 patients) after TA. Clinical and
angiographic characteristics were similar in patients treated
by adenosine or nitroprusside as compared with those
treated by saline after TA (Table 1).
Procedural data and complications. Procedural data and
intraprocedural complications are shown in Table 2.
Procedural data were similar in patients treated by adenosine
or nitroprusside as compared with those treated by saline.
TA failed and drugs or saline was infused through the
guiding catheter in 8 patients treated by adenosine, in 9
patients treated by nitroprusside, and in 7 patients treated by
saline (p ¼ 0.98 and p ¼ 0.79 vs. saline, respectively). The
rates of transient AV block not requiring pacing were higher
in patients treated by adenosine as compared with those
treated by saline, without, however, reaching the statistical
signiﬁcance level of the study (13% vs. 3%, p ¼ 0.03)
(Table 2). The rates of severe hypotension requiring vaso-
pressor drugs or intra-aortic balloon pump support were
similar in patients treated by nitroprusside and in those
treated by saline (8% vs. 6%, p ¼ 0.56) (Table 2).
Myocardial reperfusion and peak enzymatic release. Data
regarding myocardial reperfusion and peak enzyme levels are
shown in Table 3. STR >70% occurred in 71% of patients
treated by adenosine, in 54% of patients treated by nitro-
prusside, and in 51% of patients treated by saline (risk ratio:
Figure 1. Randomization Flow Chart
During the study period, 471 patients were considered for inclusion and 240 STEMI patients with TIMI ﬂow grade 0/1 were enrolled according to eligibility criteria and
randomly allocated 1:1:1 to receive adenosine (n ¼ 80), nitroprusside (n ¼ 80), or saline (n ¼ 80) given distal to the occluded site after TA. CABG ¼ coronary artery
bypass graft; ECG ¼ electrocardiogram; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction; TA ¼ thrombus aspiration;
TIMI ¼ Thrombolysis In Myocardial Infarction.
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5831.39; 95% conﬁdence interval [CI]: 1.07 to 1.79; p ¼ 0.009,
and risk ratio: 1.04; 95% CI: 0.78 to 1.40; p ¼ 0.75, aden-
osine or nitroprusside vs. saline, respectively) (Fig. 2A). Of
note, after excluding patients with TA failure, STR >70%
occurred in 76% of patients treated by adenosine, in 56% of
patients treated by nitroprusside, and in 52% of patients
treated by saline (risk ratio: 1.46; 95% CI: 1.13 to 1.89; p ¼
0.003, and risk ratio: 1.08; 95% CI: 0.80 to 1.46; p ¼ 0.62,
adenosine or nitroprusside vs. saline, respectively). Angio-
graphic MVO occurred in 18% of patients treated by aden-
osine, in 24% of patients treated by nitroprusside, and in 30%
of patients treated by saline (risk ratio: 0.58; 95% CI: 0.32 to
1.04; p¼ 0.06, and risk ratio: 0.79; 95%CI: 0.47 to 1.32; p¼
0.37, adenosine or nitroprusside vs. saline, respectively)
(Fig. 2B). Combined angiographic and ECGMVO occurred
in 8% of patients treated by adenosine, in 13% of patients
treated by nitroprusside, and in 18% of patients treated by
saline (risk ratio: 0.42; 95% CI: 0.17 to 1.05; p ¼ 0.057, andrisk ratio 0.71; 95% CI: 0.33 to 1.51; p ¼ 0.37, adenosine or
nitroprusside vs. saline, respectively) (Fig. 2C). Peak CK-MB
and TnT levels were lower in patients treated by adenosine
as compared with those treated by saline (p ¼ 0.002 and
p ¼ 0.01, respectively), whereas they were similar between
patients treated by nitroprusside as compared with those
treated by saline (p ¼ 0.99 and p ¼ 0.69, respectively).
There was no evidence that the beneﬁt with regard to the
primary endpoint was heterogeneous among baseline levels
of pre-speciﬁed covariates. There was no signiﬁcant inter-
action for any subgroups (Fig. 3).
Clinical outcome. Clinical outcome at 30 days is shown in
Table 4. MACE occurred in 10% of patients treated by
adenosine, in 14% of patients treated by nitroprusside, and
in 20% of patients treated by saline (risk ratio: 0.5; 95% CI:
0.22 to 1.10; p ¼ 0.08, and risk ratio: 0.68; 95% CI: 0.34 to
1.38; p ¼ 0.29, adenosine or nitroprusside vs. saline,
respectively).
Table 1. Baseline Characteristics of the Patients According to Treatment Group
Characteristics
Adenosine
(n ¼ 80)
Nitroprusside
(n ¼ 80)
Saline
(n ¼ 80) p Value* p Valuey
Clinical
Age, yrs 63  11 63  10 64  13 0.70 0.51
Male 62 (78) 59 (74) 59 (74) 0.71 0.99
Hypertension 43 (54) 43 (54) 48 (60) 0.52 0.52
Current smoking 48 (60) 43 (54) 45 (56) 0.75 0.87
Diabetes 20 (25) 22 (28) 17 (21) 0.71 0.46
Hypercholesterolemia 20 (25) 20 (25) 17 (21) 0.71 0.71
Family history of CAD 26 (33) 27 (34) 23 (28) 0.73 0.61
Previous CAD 16 (20) 13 (16) 19 (24) 0.71 0.32
Previous PCI 7 (9) 7 (9) 11 (14) 0.45 0.37
Previous CABG 2 (3) 1 (1) 4 (5) 0.68 0.45
Pre-infarction angina 22 (28) 20 (25) 19 (24) 0.72 0.99
Rescue PCI 2 (3) 3 (4) 2 (3) 0.99 0.98
Killip class 3 11 (14) 8 (10) 9 (11) 0.80 0.60
Total ischemic time, min 277  223 278  221 280  205 0.93 0.95
BMI, kg/m2 26  2.2 26  2.4 26  2.3 0.45 0.52
SBP, mm Hg 148  24 150  23 150  24 0.55 0.92
DBP, mm Hg 84  15 87  14 87  15 0.29 0.90
HR, beats/min 69  19 70  20 68  20 0.63 0.46
Cr clearance, ml/min/1.73 m2 62  15 65  13 64  15 0.31 0.63
Glycemia, mg/dl 118  43 123  52 120  47 0.77 0.72
Therapy on admission
Aspirin 24 (30) 26 (33) 24 (30) 0.98 0.86
Beta-blockers 14 (18) 17 (21) 17 (21) 0.69 0.99
Ace-inhibitors/AII blockers 17 (21) 13 (16) 15 (19) 0.84 0.84
Statins 11 (14) 10 (13) 10 (13) 0.98 1.00
Angiographic
Number of diseased vessels
1 35 (44) 35 (44) 38 (48)
2 24 (30) 28 (35) 24 (30) 0.84 0.80
3 21 (26) 17 (21) 18 (23)
Infarct-related vessel
LAD 37 (46) 42 (53) 36 (45)
LCX 13 (16) 15 (19) 11 (14) 0.83 0.26
RCA 30 (38) 23 (29) 33 (41)
TIMI ﬂow grade 0 72 (90) 67 (84) 65 (81) 0.18 0.84
Thrombus score 4/5 77 (96) 69 (86) 70 (88) 0.08 0.98
Proximal vessel segment 40 (50) 32 (40) 40 (50) 0.99 0.27
Values are mean  SD or n (%). *Adenosine versus saline. yNitroprusside versus saline.
ACE-inhibitors/AII blockers ¼ angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; BMI ¼ body mass index; CABG ¼
coronary artery bypass graft; CAD ¼ coronary artery disease; Cr clearance ¼ creatinine clearance; DBP ¼ diastolic blood pressure; HR ¼ heart rate;
LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary artery; PCI ¼ percutaneous coronary intervention; RCA ¼ right
coronary artery; SBP ¼ systolic blood pressure; TA ¼ thrombus aspiration; TIMI ¼ Thrombolysis In Myocardial Infarction.
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584Discussion
The results of our randomized trial show that the intracoronary
administrationof a highdose of adenosine, butnot that of a high
dose of nitroprusside, given selectively into the IRA, improves
microvascular perfusion in the setting of PPCI, as assessed by
STR, whereas the improvement of angiographic MVO and
clinical outcome does not reach statistical signiﬁcance.Adenosine is an endogenous nucleoside characterized by a
short half-life (<2 s) and by pleiotropic effects (9,10,25,26).
First, it is a potent direct vasodilator of coronary micro-
circulation through stimulation of A2 receptors (27). Second,
it exhibits anti-inﬂammatory properties against neutrophils
(28) and inhibits platelet aggregation (29). Third, adenosine
mimics ischemic pre-conditioning and limits reperfusion
injury (25,26,30). Fourth, it exhibits antiapoptotic effects and
Table 2. Procedural Data and Intraprocedural Complications According to Treatment Group
Characteristics
Adenosine
(n ¼ 80)
Nitroprusside
(n ¼ 80)
Saline
(n ¼ 80) p Value* p Valuey
Procedural data
Femoral approach 32 (40) 32 (40) 27 (34) 0.51 0.51
TA failure 8 (10) 9 (11) 7 (9) 0.98 0.79
Direct stenting after TA 37 (46) 41 (51) 33 (41) 0.63 0.27
DES implantation 32 (40) 30 (38) 30 (38) 0.87 0.98
Number of stents 1.3  0.6 1.4  0.5 1.4  0.5 0.49 0.88
Length of stented segment, mm 23.8  7.2 25.1  10 24.7  7.0 0.57 0.78
Diameter of stented segment, mm 3.1  0.5 3.1  0.5 3.1  0.5 0.85 0.91
Post-dilation 39 (49) 41 (51) 42 (53) 0.75 0.98
Intraprocedural complications
Transient AV block not requiring pacing 10 (13) 1 (1) 2 (3) 0.03 0.98
AV block requiring pacing for drug infusion 1 (1) 0 0 0.98 1.00
Transient hypotension not requiring vasopressor drugs or IABP 1 (1) 4 (5) 2 (3) 0.98 0.68
Hypotension requiring vasopressor drugs or IABP, 4 (5) 8 (8) 5 (6) 0.98 0.56
Ventricular tachycardia/ﬁbrillation 2 (3) 2 (2) 2 (3) 1.00 1.00
Chest pain/dyspnea during study administration 3 (4) 1 (1) 1 (1) 0.62 1.00
Angiographically visible distal embolization 9 (11) 7 (8) 9 (11) 1.00 0.79
Values are n (%) or mean  SD. *Adenosine versus saline. yNitroprusside versus saline.
AV ¼ atrioventricular; DES ¼ drug-eluting stent; IABP ¼ intra-aortic balloon pump; TA ¼ thrombus aspiration.
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585may stimulate angiogenesis (10,31). All these effects are
mediated by the stimulation of cell surface receptors, including
the well-known electrophysiological and algogenic effects
(10,25,26,32). Of note, although the vasodilatory, electro-
physiological, and algogenic effects of adenosine are short-
lived, the remaining effects are prolonged because they are
related to the activation of intracellular metabolites or even
modulation of gene expression (25–27). The high doses of
adenosine administered to our patients are probably high
enough to stimulate all adenosine receptors, thus activating all
pleiotropic effects potentially protective in the setting of
MVO (25–27). Furthermore, due to the short half-life of both
drugs, a bolus and infusion regimen was chosen in order to
allow a more sustained vasodilation. Of note, STR wasTable 3. Angiographic, Electrocardiographic, and Enzymatic Data According to T
Characteristics
Adenosine
(n ¼ 80)
Nitro
(n
Baseline ST-segment elevation 1.9  1.1 1.9
STR >70%z 57 (71) 43
Residual ST-segment elevation at 90 min 0.5  0.2 0.7
Time from the last dye to ECG 91  8 92
Final TIMI ﬂow grade <3 7 (9) 8
Final MBG 0–1 10 (13) 14
Final cTFC 13.0  3.7 15.2
Peak CK, mg/dl 799 (365–1234) 952 (5
Peak CK-MB, ng/ml 78.7 (45.3–112.1) 123.1 (6
Peak troponin, ng/ml 7.73 (3.01–9.97) 8.52 (1
Values are mean  SD, median (interquartile range), or n (%). *Adenosine versus saline. yNitroprusside
CK ¼ creatine kinase; CK-MB ¼ creatine kinase-MB; cTFC ¼ corrected Thrombolysis In Myoca
other abbreviations as in Table 1.improved by adenosine more than were angiographic indexes
of reperfusion, thus suggesting that effects lasting more than
those related to vasodilatation may be involved in the bene-
ﬁcial role of adenosine. Interestingly, lack of STR and
angiographic MVO have been shown to have independent
prognostic value after reperfusion (23), because they may
reﬂect different pathogenetic mechanisms. In particular,
angiographic data seem to reﬂect alteration of the microcir-
culation, whereas ECG data seem to reﬂect also the
myocardial involvement during reperfusion that needs time to
appear (33). Adenosine with its pleiotropic effects may
probably antagonize both players.
Our results are in keeping with those of previous smaller
studies that used high intracoronary doses of adenosinereatment Group
prusside
¼ 80)
Saline
(n ¼ 80) p Value* p Valuey
 1.0 1.9  1.1 0.82 0.87
(54) 41 (51) 0.009 0.75
 0.4 0.9  0.4 0.001 0.39
 7 93  5 0.83 0.85
(10) 8 (10) 0.28 1.00
(18) 19 (24) 0.06 0.43
 4.2 21.1  14.1 <0.001 <0.001
60–1667) 973 (462–2445) 0.001 0.42
5.5–213.2) 116.6 (37.9–218.9) 0.002 0.99
.94–21.05) 12.06 (2.42–16.54) 0.01 0.69
versus saline. zPrimary endpoint.
rdial Infarction frame count; MBG ¼ myocardial blush grade; STR ¼ ST-segment resolution;
Figure 2. Myocardial Reperfusion Data on Electrocardiography According
to the Treatment Group
(A) The percentages of patients are shown according to the degree of ST-
segment resolution (STR): STR <30%; STR 30% to 70%, or STR>70%. (B) The
percentages of patients are shown according to TIMI ﬂow grade 3 and
myocardial blush grade (MBG) 2 to 3, TIMI <3, or TIMI ¼ 3 and MBG 0 to 1. (C)
The percentages of patients are shown according to concordance of angi-
ography and ECG for lack of MVO (both STR >70% and no angiographic
MVO); discordance of angiography and ECG for MVO (either STR<70% or
angiographic MVO); concordance of angiography and ECG for presence of
MVO (both STR <70% and angiographic MVO). MVO ¼ microvascular
obstruction; other abbreviations as in Figure 1.
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586showing an improvement of various indexes of reperfusion
(13–16). Our results differ, however, from those of theAMISTAD I (34) and II (35) (Abciximab Before Di-
rect Angioplasty and Stenting in Myocardial Infarction
Regarding Acute and Long-Term Follow-Up I and II) trials
with IV adenosine and of 2 recent studies with intracoronary
adenosine. The AMISTAD II trial (35), in particular, failed
to show an improvement of the primary combined endpoint
of death and hospitalization for heart failure after 6 months
of IV adenosine. However, many differences exist between
our study and the AMISTAD studies. Indeed, thrombolysis
was used in all patients of the AMISTAD I trial and in
nearly 60% of patients of the AMISTAD II trial, with
no patient treated by glycoprotein IIb/IIIa inhibitors.
Furthermore, adenosine was used with an IV approach, and
it was often infused after thrombolysis (50% of patients did
not receive adenosine before thrombolysis had begun in the
AMISTAD I study). Finally, data about indexes of reper-
fusion are not provided; the authors chose to assess ﬁnal
scintigraﬁc infarct size in a subset of patients (197 patients
from the AMISTAD I trial and 243 from the AMISTAD II
trial). Of note, a reduction of infarct size was observed in
those patients treated by high-dose IV adenosine (70 mg/kg/min),
especially when the area at risk was high, and a reduction
in mortality was shown for patients treated <3 h in a sub-
study of the AMISTAD II trial (36), suggesting probably
that high-dose IV adenosine may have beneﬁcial effects,
especially when structural alterations of the microcirculation
have not occurred.
More recently, in a study carried out in 448 patients,
Fokkema et al. (17) failed to ﬁnd a beneﬁcial effect of
intracoronary adenosine given after TA on both angiographic
and ECG indexes of myocardial reperfusion. However, the
dose of adenosine (240 mg) was much smaller than that used
in our study; furthermore, adenosine was injected through
the guiding catheter, thus further reducing the effective
drug concentration in the IRA. Interestingly, in our study,
adenosine was superior to placebo in regard to the primary
endpoint after also excluding those patients who received the
drugs through the guiding catheter due to TA failure.
Similarly, in a study carried out in 112 patients, Desmet
et al. (18) failed to show a reduction in MVO or an increase
in myocardial salvage, as assessed by cardiac magnetic
resonance by using high doses of intracoronary adenosine
(4 mg) distal to the occlusion site of the culprit lesion.
However, adenosine was injected without previous TA and
before balloon dilation, thus distal embolization could have
overridden the protective effect of adenosine. Of note, IV
adenosine given before revascularization failed to improve
clinical outcome in the AMISTAD II study (35). Taken
together, these studies suggest that only high doses of
adenosine reaching coronary microcirculation in the IRA
territory immediately after ﬂow restoration are able to
improve MVO, as assessed by STR.
Our subgroup analysis shows an homogeneous effect of
adenosine in all explored subgroups, thus conﬁrming the
Figure 3. Risk Ratio for the Primary Endpoint, According to Pre-Speciﬁed Clinical or Angiographic Subgroups
Numbers in the TA alone and the TA and adenosine columns refer to patients that reached the primary endpoint over the entire number of patients of each treatment
group. The p for interaction is reported. CI ¼ conﬁdence interval; LAD ¼ left anterior descending coronary artery; TA ¼ thrombus aspiration.
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587robustness of its beneﬁcial effects in the overall population.
Notably, despite the high doses, adenosine administration in
our study was safe; in particular, the episodes of AV block
were infrequent and transient, thus allowing the operators to
complete its infusion in all patients.
In our study, we failed to show a beneﬁcial effect of
nitroprusside on MVO. This ﬁnding is consistent with that
of the only randomized study, previously performed by AmitTable 4. Clinical Outcome According to Treatment Group
Characteristics
Adenosine
(n ¼ 80)
Nitroprusside
(n ¼ 80)
Saline
(n ¼ 80) p Value* p Valuey
Death 2 (3) 2 (3) 3 (4) 0.98 0.98
MI 1 (1) 2 (3) 3 (4) 0.62 0.98
TLR 4 (5) 5 (6) 6 (8) 0.75 0.98
HF 1 (1) 2 (3) 4 (5) 0.37 0.68
MACE 8 (10) 11 (14) 16 (20) 0.08 0.29
Any bleeding 12 (15) 12 (15) 12 (15) 0.99 0.99
GUSTO bleeding
classiﬁcation
Severe 1 (1) 2 (3) 1 (1) 0.99 0.98
Moderate 2 (3) 2 (3) 3 (4) 0.98 0.98
Minor 9 (11) 8 (10) 8 (10) 0.98 0.99
Values are n (%). *Adenosine versus saline. yNitroprusside versus saline.
GUSTO ¼ Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded
Coronary Arteries; HF ¼ heart failure; MACE ¼ major adverse cardiac events; MI ¼ myocardial
infarction; TLR ¼ target lesion revascularization.et al. (21) who injected 60 mg of nitroprusside before balloon
dilation and distal to the occlusion site in 98 patients.
Although in our study we used higher doses of nitroprusside,
we failed to show improvement of indexes of MVO. The
causes of lack of efﬁcacy can be multiple. First, nitroprusside
was given concurrently with glycoprotein IIb/IIIa inhibitors,
thus its antiplatelet effects (37) might have been overridden
by that conferred by abciximab. Second, doses of nitroprus-
side may have been inadequate. Indeed, some studies suggest
that nitroprusside may improve coronary ﬂow by increasing
the dose up to 700 mg in the attempt to reverse angiographic
MVO (19). The safety of such high doses has not been tested,
however, in large trials. Finally, nitroprusside does not exhibit
the several pleiotropic effects of adenosine that may play
a critical role in patients at risk of MVO.
Study limitations. Ours is an open-label study, enrolling
a small number of patients, which may have been under-
powered for some statistical associations. In particular, our
study was not powered to provide information on clinical
endpoints. The inclusion of patients with ischemic time up
to 12 h may have blunted the protective effects of adenosine,
as ischemic cell death has already occurred. This is consis-
tent with the substudy of the AMISTAD II trial mentioned
in the previous text (36) and with the results of our subgroup
analysis, which showed a greater STR in patients presenting
<3 h of symptom onset. Furthermore, the inclusion of
patients treated by rescue PCI may have diluted the
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588beneﬁcial effects of adenosine on STR, because rescue
patients may have a window of thrombolytic-induced
reperfusion with reperfusion injury having already occurred
at the time of adenosine administration. However, we
included 7 rescue patients only. Thus, the impact of such
a variable on our results should be trivial. Additionally, the
lack of cardiac magnetic resonance evaluation of both MVO
and infarct size is an important limitation of the study.
However, ECG indexes of MVO have been shown to
correlate with those provided by cardiac magnetic resonance,
whereas angiographic indexes have a less robust correlation,
the reason why we chose STR as the primary endpoint of our
study (38,39). The high rate of ineligible patients is another
limitation of our study; however, we aimed to include
patients presenting with TIMI ﬂow grade 0/1 on admission
who are known to be those at highest risk of MVO. The role
of intracoronary drugs in the prevention of MVO in patients
with open vessels and TIMI ﬂow grade 2/3 may be a matter
of future studies. Moreover, we were not able to evaluate the
interaction between thrombus burden and therapies against
MVO. Indeed, we performed thrombus score assessment
before wiring the vessel, thus possibly underestimating
thrombus burden in occluded vessels (40). Finally, when we
designed the study, the use of bivalirudin plus bail-out
glycoprotein IIb/IIIA inhibitors was not a Class I recom-
mendation, thus our strategy should be compared against
this regimen.
Conclusions
The incidence of MVO after PPCI may be lowered by the
use of glycoprotein IIb/IIIa antagonists (41) and by the
addition of manual TA (6,24). The results of the present
study show that the additional intracoronary administration
of a high dose of adenosine may further improve STR up to
70%. Future larger studies with clinical endpoints are war-
ranted to conﬁrm the beneﬁt of intracoronary administration
of a high dose of adenosine in addition to glycoprotein IIb/
IIIa antagonist administration and TA in the setting of
PPCI or rescue PCI.Reprint requests and correspondence: Dr. Giampaolo Niccoli,
Institute of Cardiology, Catholic University of the Sacred Heart,
Largo F. Vito 1, 00168 Rome, Italy. E-mail: gniccoli73@hotmail.it.
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For an expanded Methods section, please see the online version of
this paper.
